Mohammad Asim

Dr Mohammad Asim

Senior Lecturer (Associate Professor) in Cancer Biology & Therapeutics

Academic and research departments

School of Biosciences.


Areas of specialism

Cancer Biology ; Transcription & Translational Biology; Prostate Cancer; Cancer Therapeutics; Nuclear hormone receptors; Proteomics; Oncogenic Kinases; Drug Discovery

University roles and responsibilities

  • Academic Integrity Officer
  • Visiting Tutor Professional Training Year
  • Personal Tutor
  • MD/PhD examiner
  • Module Organiser
  • Research Supervisor

    My qualifications

    Fellowship of the Higher Education Academy of the United Kingdom
    Higher Education Academy of the United Kingdom
    October 2003-October 2006
    Doctor of Philosophy (PhD)
    PhD thesis studying the role of signal transduction and transcriptional cofactors in the regulation of androgen receptor function in prostate cancer
    Justus Liebig University Germany
    August 1999-July 2001
    MSc in Biotechnology
    Hamdard University, New Delhi, India
    August 1995- July 1998
    BSc in Botany, Chemistry, Zoology
    MJP Rohilkhand University, Bareilly, India

    Affiliations and memberships

    1. American Association for the Advancement of Science
    2. American Association for Cancer Research
    3. Higher Education Academy of the United Kingdom
    4. The Royal Society of Biology of the United Kingdom


    In the media

    Dr. Asim elected Fellow of the Royal Society of Biology.
    Dr. Asim awarded SHOUT (Student Honouring Outstanding University Talent) award on teaching excellence from the University of Surrey Student Union.
    Recurrence of prostate cancer could be reduced thanks to exciting new discovery
    Lead discoverer
    University of Surrey Webpage
    Choline kinase alpha as Androgen Receptor Chaperone and Prostate Cancer Target
    Lead investigator
    The American Society of Clinical Oncology Post
    Cancer research with Dr Mohammad Asim
    University of Surrey News


    Research interests



    Bizga Nicolescu RC, Maylin Z, Perez Areales FJ, Iegre J, Pandha H, Asim M*, Spring DR (2022). Hybrid androgen receptor inhibitors outperform enzalutamide and EPI-001 in in vitro models of prostate cancer drug resistance. ChemMedChem. 2022 Oct 27. doi: 10.1002/cmdc.202200548. Online ahead of print.

    Liu DS, Yang Q, Asim M, Krell J, Frampton AE (2022). The Clinical Significance of Transfer RNAs present in Extracellular Vesicles. Int J Mol Sci. 28;23:3692.

    Miller KJ, Asim M* (2022). Unravelling the Role of Kinases that Underpin Androgen Signalling in Prostate Cancer. Cells 11:952.

    Goel S, Bhatia V, Carskadon S, Gupta S, Asim M, Morrissey C, Palanisamy N, Ateeq B (2021). A transcriptional network involving ERG and AR orchestrates Distal-Less Homeobox 1 mediated prostate cancer progression Nature Communications. 12:5325.

    Maylin Z, Nicolescu RCB, Pandha H, Asim M* (2021). Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease. Translational Oncology 14:101115.

    Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M* (2019). A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene.38(7):1136-1150. PMID: 30237440.

    Asim M*, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T. (2017) Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications. 29;8(1):374. PMID: 28851861.

    Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG. (2016) HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget. 15;7(46):74734-74746. PMID: 27732966.

    Asim M*, Massie CE, Neal DE. (2016) Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. Molecular & Cellular Oncology. 3(3):e1140262. PMID: 27314091.

    Asim M*, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Selth LA, Zecchini HI, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Zecchini V, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Baniahmad A, Carroll JS, Griffiths JR, Tavaré S, McEwan IJ, Mills IG, Tilley WD, & Neal DE. (2016) Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target Journal of the National Cancer Institute. 11;108(5). PMID: 26657335.

    Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG. (2015) A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for Monocarboxylate Transporters as metabolic targets for therapy. Journal of Pathology. 236(4):517-30. PMID: 25875424.

    Mahmood I, Ahmad I, Asim M, Lopes TT, Costa L (2014) Silica-coated iron oxide nano-particles in vitro genotoxicity assessment and its interference with mercury co-exposure in European eel Anguilla anguilla LEnvironmental Science and Pollution Research. 22(5):3687-96. PMID: 25256583.

    Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Zecchini HI, Rao R, Scott H, Boren J, Massie C, Asim M, Brindle K, Griffiths J, Frezza C, Neal D, Mills IG. (2014) Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancerEMBO Journal. 33(12):1365-82. PMID: 24837709.

    Eckey M, Kraft F, Kob R, Escher N, Asim M, Fischer H, Fritsche MK, Melle C, Baniahmad A. (2013) The corepressor activity of Alien is controlled by CBP/p300FEBS Journal. 280(8):1861-8. PMID: 23441852.

    Altay G, Asim M, Markowetz F, Neal DE. (2011) Differential C3NET reveals disease networks of direct physical interactions. BMC Bioinformatics Jul 21;12:296. PMID: 21777411.

    Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H, Baniahmad A. (2011) Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinaseJournal of Biological Chemistry Oct 28;286(43):37108-17. PMID: 21856747.

    Siddiqui IA, Asim M (Joint first), Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. (2011) Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB Journal Apr;25(4):1198-207. PMID: 21177307.

    Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, Mukhtar H. (2009) Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signalingCarcinogenesis May;30(5):808-17. PMID: 19233958.

    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A. (2009) Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Journal of Molecular Endocrinology. May;42(5):429-35. PMID: 19223455.

    Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H. (2009) Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Research Mar 1;69(5):1712-6. PMID: 19223530.

    Hafeez BB, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H. (2009) Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clinical Cancer Research Jan 15;15(2):452-9. PMID: 19147749.

    Khan N, Asim M (Joint first), Afaq F, Abu Zaid M, Mukhtar H. (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Research Oct 15;68(20):8555-63. PMID: 18922931.

    Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. (2008) Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene Jun 5;27(25):3596-604. PMID: 18223692.

    Hafeez BB, Asim M, Siddiqui IA, Adhami VM, Murtaza I, Mukhtar H. (2008) Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: a new weapon to blunt prostate cancer growthCell Cycle; 7(21):3320-6. PMID: 1894874.

    Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M, Mukhtar H. (2008) A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Research 2008 Oct 15;68(20):8564-72. PMID: 18922932.

    Saleem M, Maddodi N, Abu Zaid M, Khan N, bin Hafeez B, Asim M, Suh Y, Yun JM, Setaluri V, Mukhtar H. (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clinical Cancer Research Apr 1;14(7):2119-27. PMID: 18381953.

    Siddiqui IA, Shukla Y, Adhami VM, Sarfaraz S, Asim M, Hafeez BB, Mukhtar H. (2008) Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer modelPharm Res. Sep;25(9):2135-42. PMID: 18317887.

    Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A. (2008) Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer developmentFASEB Journal Apr;22(4):1258-67.PMID: 17991730.

    Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H. (2008) Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene Mar 27;27(14):2055-63. PMID: 17998943.

    Siddiqui IA, Saleem M, Adhami VM, Asim M, Mukhtar H. (2007) Tea beverage in chemoprevention and chemotherapy of prostate cancerActa Pharmacol Sin. Sep;28(9):1392-408. PMID: 17723173.

    Gessner G, Schönherr K, Soom M, Hansel A, Asim M, Baniahmad A, Derst C, Hoshi T, Heinemann SH. (2005) BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cellsJ Membr Biol. Dec;208(3):229-40. PMID: 16604468.

    Papaioannou M, Reeb C, Asim M, Dotzlaw H, Baniahmad A. (2005) Co-activator and corepressor interplay on the human androgen receptor. Andrologia. Dec;37(6):211-2.

    * Denotes publications as the corresponding author